Role of renal cortical neovascularization in experimental hypercholesterolemia.
Hypercholesterolemia induces renal inflammation and neovascularization, associated with renal endothelial dysfunction and injury. Neovascularization might conceivably represent a defense mechanism to sustain renal perfusion. Therefore, the present study was designed to test the hypothesis that preventing neovascularization using thalidomide, a potent anti-inflammatory and antiangiogenic agent, would impair basal renal hemodynamics in experimental hypercholesterolemia. Single-kidney function and hemodynamic responses to endothelium-dependent challenge were assessed in pigs after 12 weeks of hypercholesterolemia, hypercholesterolemia chronically supplemented with thalidomide (4 mg/kg per day), and normal controls. Renal microvascular architecture was then studied ex vivo using 3D microcomputed tomography imaging and inflammation, angiogenesis, and oxidative stress explored in renal tissue. The density of larger microvessels (200 to 500 microm) was selectively decreased in hypercholesterolemia plus thalidomide and accompanied by a decreased fraction of angiogenic, integrin beta(3)-positive microvessels (9.9%+/-0.9% versus 25.5%+/-1.7%; P<0.05 versus hypercholesterolemia), implying decreased angiogenic activity. Furthermore, thalidomide increased renal expression of endothelial NO synthase and decreased tumor necrosis factor-alpha and renal inflammation but did not decrease oxidative stress. Thalidomide also decreased basal renal blood flow and glomerular filtration rate but normalized the blunted renal hemodynamic responses in hypercholesterolemia. Attenuated inflammation and pathological angiogenesis achieved in hypercholesterolemia by thalidomide are accompanied by restoration of renovascular endothelial function but decreased basal renal hemodynamics. This study, therefore, suggests that neovascularization in the hypercholesterolemic kidney is a compensatory mechanism that sustains basal renal vascular function.
Chade
Alejandro R
AR
Division of Nephrology and Hypertension, Mayo Clinic College of Medicine, Rochester, MN 55905, USA.
Krier
James D
JD
Galili
Offer
O
Lerman
Amir
A
Lerman
Lilach O
LO
D020533:Angiogenesis Inhibitors / Q000494:pharmacology; D000818:Animals; D050197:Atherosclerosis / Q000473:pathology / Q000503:physiopathology; D001794:Blood Pressure / Q000187:drug effects; D049109:Cell Proliferation / Q000187:drug effects; D004195:Disease Models, Animal; D004730:Endothelium, Vascular / Q000187:drug effects / Q000473:pathology / Q000503:physiopathology; D005919:Glomerular Filtration Rate / Q000187:drug effects; D006937:Hypercholesterolemia / Q000150:complications / Q000503:physiopathology*; D007249:Inflammation / Q000473:pathology / Q000503:physiopathology; D007672:Kidney Cortex / Q000098:blood supply* / Q000378:metabolism / Q000503:physiopathology*; D008833:Microcirculation / Q000187:drug effects; D009389:Neovascularization, Pathologic / Q000209:etiology / Q000503:physiopathology*; D052250:Nitric Oxide Synthase Type III / Q000378:metabolism; D012039:Regional Blood Flow / Q000187:drug effects; D013552:Swine; D013792:Thalidomide / Q000494:pharmacology
D020533:Angiogenesis Inhibitors; D013792:Thalidomide; D052250:Nitric Oxide Synthase Type III